We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01180959
Recruitment Status : Active, not recruiting
First Posted : August 12, 2010
Last Update Posted : October 6, 2017
Genentech, Inc.
OSI Pharmaceuticals
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : April 2019
  Estimated Study Completion Date : April 2020